Tsangs Group is pleased to announce that, our portfolio company, TECC Capital Plc, now renamed EDX Medical Group, (“the Company”) has completed its acquisition of EDX Medical Limited on 14 November 2022.
The Company (TIDM: EDX), which develops digital diagnostic products and services for use in testing for cancer, heart disease, neurology and infectious diseases, announced that 250,833,333 ordinary shares of 1 pence each (“Ordinary Shares”) were admitted to trading on the Access Segment of the AQSE Growth Market (“Admission”).
In connection with Admission, the Company has raised £1.2 million through a placing of 20,000,000 Ordinary Shares at a price of 6 per share.
EDX Medical Ltd was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience in the sector, specialising in cancer treatments and diagnostics.
“Sir Christopher Evans is one of the pioneer leaders in medical research, and an innovative entrepreneur who aims to benefit the society with his knowledge and experience. I firmly believe that the acquisition project could make progress and create positive impact to the world,” commented Patrick Tsang, Chairman of Tsangs Group.
For more information about EDX Medical Group, please visit: https://www.edxmedical.co.uk.
About Tsangs Group
Tsangs Group is an innovation-focused global family office that bridges East and West. Our mission is to invest in global opportunities that allow us to exert positive influence and drive positive impact in Hong Kong, Asia and beyond.
Headquartered in Hong Kong, Tsangs Group has direct investments across the world, we seek out positive impact investments that reflect our values of innovation, sustainability, and togetherness. Our strategy is opportunistic and both sector and location agnostic.
From fintech to entertainment to space travel, we are always investigating, analysing, and supporting the cutting edge of global innovation and development.